U.S. FDA Approves First Drug for Graft vs Host Disease Prevention

The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Bristol Myers Squibb Co’s drug Orencia to prevent a potentially fatal complication that could occur after a stem cell transplant. Read More